Effect of probiotic Lactobacillus strains in children with atopic dermatitis

Rosenfeldt, Vibeke; Benfeldt, Eva; Nielsen, Susanne Dam; Michaelsen, Kim Fleischer; Jeppesen, Dorthe Lisbeth; Valerius, Niels Henrik; Pærregaard, Anders

doi:10.1067/mai.2003.389

Cited by 523 publications

(384 citation statements)

References 23 publications

Supporting

Mentioning

358

Contrasting

Unclassified

Order By: Relevance

“…133 Cytokine production by PBMCs in response to polyclonal stimuli was not affected in participants of trials where probiotic supplementation did not show a significant effect. 134,135 In contrast, improvements in SCORAD scores were associated with increased IFN-γ production in studies where probiotic supplementation was beneficial at least in certain subgroups of patients. 136,137 In addition, the induction of low-grade infl ammation, as indicated by increased serum CRP and IL-6 levels, has been proposed as a mechanism.…”

Section: Probiotics In Allergic Diseasesmentioning

confidence: 91%

Probiotics and immunity

et al. 2009

View full text Add to dashboard Cite

Probiotics are defi ned as live microorganisms that, when administered in adequate amounts, confer a health benefi t on the host, including the gastrointestinal tract. While this benefi cial effect was originally thought to stem from improvements in the intestinal microbial balance, there is now substantial evidence that probiotics can also provide benefi ts by modulating immune functions. In animal models, probiotic supplementation is able to provide protection from spontaneous and chemically induced colitis by downregulating infl ammatory cytokines or inducing regulatory mechanisms in a strain-specifi c manner. In animal models of allergen sensitization and murine models of asthma and allergic rhinitis, orally administered probiotics can straindependently decrease allergen-specifi c IgE production, in part by modulating systemic cytokine production. Certain probiotics have been shown to decrease airway hyperresponsiveness and infl ammation by inducing regulatory mechanisms. Promising results have been obtained with probiotics in the treatment of human infl ammatory diseases of the intestine and in the prevention and treatment of atopic eczema in neonates and infants. However, the fi ndings are too variable to allow fi rm conclusions as to the effectiveness of specifi c probiotics in these conditions.

show abstract

Section: Probiotics In Allergic Diseasesmentioning

confidence: 91%

Probiotics and immunity

et al. 2009

View full text Add to dashboard Cite

show abstract

“…This was recently demonstrated with Bifidobacterium animalis subsp lactis BB-12 as well as L. reuteri ATCC 55730 (Weizman et al, 2005). It has also been suggested that probiotics may alleviate clinical symptoms of pediatric atopic diseases (Isolauri et al, 2000;Kalliomäki et al, 2001Kalliomäki et al, , 2003Rosenfeldt et al, 2003;Rosenfeldt et al, 2004) and modulate immune functions (Schiffrin et al, 1995;Fukushima et al, 1998;Blum and Schiffrin, 2003;Hart et al, 2004;Valeur et al, 2004). Concerning the effect on blood lipids contradictory results has been reported.…”

Section: Introductionmentioning

confidence: 99%

Dose–response study of probiotic bacteria Bifidobacterium animalis subsp lactis BB-12 and Lactobacillus paracasei subsp paracasei CRL-341 in healthy young adults

Larsen

Nielsen²,

Kæstel³

et al. 2006

Eur J Clin Nutr

109

View full text Add to dashboard Cite

Objective: This study was performed to investigate the dose-response effects of supplementation with Bifidobacterium animalis subsp lactis (BB-12) and Lactobacillus paracasei subsp paracasei (CRL-431) on blood lipids, recovery from feces and bowel habits. Changes of the fecal microflora was analyzed in the 10 10 CFU/day probiotic and placebo group. Design: The study was designed as a randomized, placebo-controlled, double-blinded, parallel dose-response study. Subjects: Healthy young adults (18-40 years) were recruited by advertising in local newspapers. Of the 75 persons enrolled, 71 (46 women, 25 men, mean age 25.6 years (range 18-40 years)) completed the study. Intervention: The volunteers were randomly assigned into five groups receiving either placebo or a mixture of the two probiotics in the concentration of 10 8 , 10 9 , 10 10 or 10 11 CFU/day in 2 weeks run-in period, 3 weeks intervention and 2 weeks wash-out. Diary reporting bowel habits and well being (abdominal bloating, flatulence and headache) was kept for all 7 weeks and blood lipids, fecal recovery of BB-12 and CRL-431, as well as fecal microflora was tested before, immediately and 2 weeks after intervention. Results: The fecal recovery of BB-12 increased significantly (Po0.001) with increasing dose. In the group receiving 10 11 CFU/ day BB-12 was recovered from 13 out of 15 volunteers. CRL-431 was not recovered in any of the fecal samples. Supplementation with probiotics did not change the fecal bacterial composition. A significant linear increase in fecal consistency (looser stool) with increasing probiotic dose (P ¼ 0.018) was observed. No overall dose-response effect was found on the blood lipids. High doses of probiotics were well tolerated. Conclusion: A dose-related recovery of BB-12 from feces was observed. Sponsorship: The study was sponsored by Chr. Hansen A/S, Hoersholm, Denmark. Keywords: dose-response study; probiotics; cholesterol; recovery from feces; constipation European Journal of Clinical Nutrition IntroductionIt is generally accepted that the composition of the intestinal microflora influences the health and well being of humans. With the many publications showing beneficial effects of probiotic bacteria, there has been an increasing interest in the mechanism behind. Most clinical studies have tested only one dose of probiotics, ranging from 4 Â 10 8 CFU/day for determination of gastrointestinal colonization and immune modulation (Valeur et al., 2004) Contributors: DCE, CNL and KFM wrote the protocol. DCE performed the study. CNL did the microbiological analysis of fecal samples and study product. EB performed the fluorescent whole cell hybridization of BB-12 like colonies. MB performed the PFGE of CRL-431 like colonies. PK performed the statistical analysis. CNL and SN wrote the first draft of the paper and all contributors participated in the revision and final approval of the paper.

show abstract

“…(Viljanen et al, 2005b;Sistek et al, 2006). These studies did not detect significant SCORAD score improvement although in the crossover study of Rosenfeldt et al (2003), which included children older than those in the other studies, patients felt better according to their subjective evaluations. Nevertheless, a pronounced decrease in SCORAD score was observed in patients with a positive skin prick-test response and increased IgE levels (Viljanen et al, 2005b;Rosenfeldt et al, 2003;Sistek et al, 2006).…”

Section: Clinical Impact Of Probiotics In Atopic/allergic Diseases 4mentioning

confidence: 73%

“…Some quality of life scales are also used, for example the Infant Dermatitis Quality Of Life (IDQOL), Dermatitis Family Impact (DFI), and Dermatitis Family Impact Questionnaire (DFIQ) scores (Gerasimov et al, 2010;Weston et al, 2005) scores. The age range of subjects included varies between studies: around weaning (median 5 months old) (Brouwer et al, 2006;Isolauri et al, 2000;Kirjavainen et al, 2003;Viljanen et al, 2005b;Gruber et al, 2007), around 1 year old (Weston et al, 2005;Folster-Holst et al, 2006), and around 5 years old (Rosenfeldt et al, 2003(Rosenfeldt et al, , 2004Sistek et al, 2006;Woo et al, 2010). Seven of these publications describe effects of Lactobacillus rhamnosus GG LGG in infants but report contradictory results (Brouwer et al, 2006;Isolauri et al, 2000;Kirjavainen et al, 2003;Viljanen et al, 2005b;Gruber et al, 2007;Folster-Holst et al, 2006;Nermes et al, 2011).…”

Section: Clinical Impact Of Probiotics In Atopic/allergic Diseases 4mentioning

confidence: 99%

“…In the last of these studies, the effects of L. fermentum VRI-003 were found to persist two months after the end of supplementation. Four studies used a L. rhamnosus strain (not LGG) alone (Brouwer et al, 2006) or mixed with L. reuteri (Rosenfeldt et al, 2003) or with other Lactobacillus sp. and Bifidobacterium sp.…”

Section: Clinical Impact Of Probiotics In Atopic/allergic Diseases 4mentioning

confidence: 99%

See 1 more Smart Citation